Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Lexaria Bioscience Corp (NQ: LEXX )

2.150 +0.060 (+2.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates Productive Year for Blood Pressure Drug Solution with Eye on Advancing Clinical Studies in 2022
Via Investor Brand Network
Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received approval from the... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Independent Review Board Approval for Its Most Ambitious, Comprehensive Human Study Yet
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers ContraFect (NASDAQ:CFRX) stock mo... 
Via Benzinga
Lexaria Bioscience Increases Investor Visibility with SRAX
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The strategic move to incorporate... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Increases Investor Visibility with SRAX (NASDAQ: SRAX)
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers ContraFect (NASDAQ:CFRX) stock in... 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Increases Investor Visibility with SRAX Inc. (NASDAQ: SRAX)
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals One Drug Class at a Time
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals One Drug Class at a Time
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Announces Approval from Independent Review for DehydraTECH-CBD Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has received Independent Review Board (“IRB”) approval for its planned DehydraTECH-... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Announces Approval from Independent Review for DehydraTECH-CBD Study
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Approval from Independent Review Board for DehydraTECH-CBD Human Clinical Study
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Approval from Independent Review Board for DehydraTECH-CBD Human Clinical Study
Via Investor Brand Network
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
• Dosing is expected to begin by April, 2022 KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Bioscience Expects Study Results to Show Patented Tech's Value in Treating Hypertension
Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Expects Study Results to Show Patented Tech’s Value in Treating Hypertension
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expects Study Results to Show its Patented Tech’s Value in Treating Hypertension Patients
Via Investor Brand Network
Lexaria Bioscience Announces Major Discovery; Increasing Effectiveness of Orally Administered CBD
In a recent human clinical trial, HYPER-H21-2, DehydraTECH-CBD reduced arterial stiffness, potentially broadening Lexaria’s application’s ability to treat... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Announces Major Discovery; Increasing Effectiveness of Orally Administered CBD
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Major Discovery; Increasing the Effectiveness of Orally Administered CBD
Via Investor Brand Network
Lexaria Bioscience (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM)
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets
Via Investor Brand Network
Lexaria's DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study
Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood... 
Via Benzinga
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study
Via Investor Brand Network
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Media Agreement with SRAX Inc. (NASDAQ: SRAX)
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Reduces Arterial Stiffness in Study HYPER-H21-2 Broadening Applications Beyond Hypertension
Via Investor Brand Network
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has... 
From Lexaria Bioscience Corp.
Via AccessWire
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.